Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162165 | 0.78 | TSHR (0.57) | KEAP1NFE2L2KMT2AMAPTTP53 | |
| SCHEMBL790693 | 0.77 | SLC40A1 (0.59) | SLC40A1GLO1KEAP1NFE2L2KMT2A | |
| SCHEMBL3447394 | 0.74 | ALDH1A1 (0.59) | SLC40A1GLO1KEAP1NFE2L2KMT2A | |
| SCHEMBL30286771 | 0.73 | MET (0.49) | SLC40A1MAPTALDH1A1POLBBRD4 | |
| SCHEMBL20339047 | 0.73 | MET (0.49) | SLC40A1MAPTALDH1A1POLBBRD4 | |
| SCHEMBL17813853 | 0.73 | MAPT (0.44) | SLC40A1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL9954363 | 0.72 | CCR2 (0.51) | SLC40A1GLO1ALDH1A1 | |
| SCHEMBL5015931 | 0.72 | KEAP1 (0.68) | SLC40A1KEAP1NFE2L2KMT2AALDH1A1 | |
| SCHEMBL12474917 | 0.71 | KMT2A (0.65) | SLC40A1KEAP1NFE2L2KMT2AALDH1A1 | |
| SCHEMBL27182584 | 0.71 | MAPT (0.46) | KMT2AMAPTTP53ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360726-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360726-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360726-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016090317-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360726-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | SLC40A1 3533/4885GLO1 1707/4885KEAP1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.